TET2 and acute myeloid leukemia: This was further justified by the fact that also persistent/acquired IDH1/2 or SRSF2 mutations had no impact on survival along with mutations in DNMT3A and TET2. ASXL1 mutations are a rare event in NPM1mut AML and were not included in this group [16, 17].